drugset / Trial / NCT02078726

Glucagon Use in Colonoscopies

NCT02078726

Phase 4 Completed 100 enrolled University of California, San Francisco
RandomizedParallel-groupDouble-blindDiagnostic

Summary

The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.

Timeline

Start
2014-04
Primary completion
2018-05
Completion
2018-05

Publications

  • Results Anupam Aditi, Trilokesh Dey Kidambi, Angel Espinoza, Nicholas Crowley, Alex Rodas, John Patrick Cello. Glucagon Shortens Cecal Intubation Time and Total Procedure Time During Colonoscopy: A Prospective, Double-Blind Placebo Controlled Randomized Trial. Biomedical Journal of Scientific & Technical Research. 2019; 22(2).

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glucagon Peptide 1 mg Intravenous

Indications